The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Kotov S.V.
Vladimirsky Moscow Regional Research Clinical Institute
Voronkov P.B.
Multidisciplinary Medical Center LLC «OrKli»
Popova V.V.
Saint Petersburg State Paediatric Medical University
Zubkova T.G.
Smorodintsev Research Institute of Influenza
Kiselev A.V.
Semenov Institute of Chemical Physics
Efficacy and safety of treatment with ampasse: the results of a randomized, double-blind, placebo-controlled trial in patients with chronic cerebrovascular disorders
Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(5): 26‑32
Views: 4815
Downloaded: 89
To cite this article:
Skoromets AA, Kotov SV, Voronkov PB, Popova VV, Zubkova TG, Kiselev AV. Efficacy and safety of treatment with ampasse: the results of a randomized, double-blind, placebo-controlled trial in patients with chronic cerebrovascular disorders. S.S. Korsakov Journal of Neurology and Psychiatry.
2021;121(5):26‑32. (In Russ.)
https://doi.org/10.17116/jnevro202112105126
To assess the efficacy and safety of the drug ampasse in the treatment of patients with chronic cerebrovascular disorders (CCVD).
A multicenter, randomized, double-blind, placebo-controlled, confirmatory study of the efficacy and safety of ampasse (phase III) was conducted in 124 patients aged 50 to 75 years. The main group (MG) — 62 patients, received the test drug ampasse, solution for intravenous administration, 5 mg/ml, at a dose of 5 ml (25 mg), intravenously bolus slowly, the duration of treatment was 15 days. Control group (CG) — 62 patients, received comparison drug: placebo (0.9% sodium chloride-5 ml).
All 124 patients fully completed the procedures and visits, there were no dropouts from the study. The proportion of patients who reached the primary endpoint (an increase in the score by 2 or more points on the MoCA scale) was 83.87% in MG and 22.58% in CG, that is, the efficacy of therapy in MG was 61.29% higher than in CG (p<0.001), and good tolerability of the drug was proved. The secondary endpoint is an increase in quality of life (QOL) on the SF-36 V2 scale on Day 31. In MG, there was a statistically significant improvement in all indicators of QOL compared to the baseline. When assessing the safety spectrum, the proportion of patients who had adverse events was 14.52% in MG and 8.06% in CG (p=0.395).
Ampasse has a positive effect on cognitive functions and QOL, does not increase the frequency of adverse events in patients with CCVD compared to placebo, does not cause significant side effects, and is well tolerated by patients.
Keywords:
Authors:
Kotov S.V.
Vladimirsky Moscow Regional Research Clinical Institute
Voronkov P.B.
Multidisciplinary Medical Center LLC «OrKli»
Popova V.V.
Saint Petersburg State Paediatric Medical University
Zubkova T.G.
Smorodintsev Research Institute of Influenza
Kiselev A.V.
Semenov Institute of Chemical Physics
Received:
19.03.2021
Accepted:
27.04.2021
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.